Détermination du statut KRAS associé au statut EGFR pour la prise en charge thérapeutique des cancers bronchiques.

L. Lacroix; B. Besse; J. M. Bidart; J. Bosq

doi:10.1684/bdc.2009.0999

Détermination du statut KRAS associé au statut EGFR pour la prise en charge thérapeutique des cancers bronchiques.

L. Lacroix, B. Besse, J. M. Bidart, J. Bosq

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

3 Citations (Scopus)

Résumé

Interest for development of molecular biomarkers tends to increase in clinical management of lung cancer. Indeed implementation in clinics of new molecules targeting epithelial growth factor (EGFR) such as erlotinib or gefitinib, rise several questions regarding the potential value of EGFR and KRAS mutations to predict therapeutic response. In the current review, we discuss the utilization of such biomarkers regarding published clinical data and the possibilities versus limitations associated with analyses performed in molecular laboratory on a daily setting basis.

Titre traduit de la contribution	KRAS status versus EGFR status in lung cancer therapy
langue originale	Français
Pages (de - à)	S75-83
journal	Bulletin du Cancer
Volume	96 Suppl
Les DOIs	https://doi.org/10.1684/bdc.2009.0999
état	Publié - 1 janv. 2009

Accès au document

10.1684/bdc.2009.0999

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{7e2867f6610b4f7496316f43464488a4,

title = "D{\'e}termination du statut KRAS associ{\'e} au statut EGFR pour la prise en charge th{\'e}rapeutique des cancers bronchiques.",

abstract = "Interest for development of molecular biomarkers tends to increase in clinical management of lung cancer. Indeed implementation in clinics of new molecules targeting epithelial growth factor (EGFR) such as erlotinib or gefitinib, rise several questions regarding the potential value of EGFR and KRAS mutations to predict therapeutic response. In the current review, we discuss the utilization of such biomarkers regarding published clinical data and the possibilities versus limitations associated with analyses performed in molecular laboratory on a daily setting basis.",

author = "L. Lacroix and B. Besse and Bidart, {J. M.} and J. Bosq",

year = "2009",

month = jan,

day = "1",

doi = "10.1684/bdc.2009.0999",

language = "Fran{\c c}ais",

volume = "96 Suppl",

pages = "S75--83",

journal = "Bulletin du Cancer",

issn = "0007-4551",

}

TY - JOUR

T1 - Détermination du statut KRAS associé au statut EGFR pour la prise en charge thérapeutique des cancers bronchiques.

AU - Lacroix, L.

AU - Besse, B.

AU - Bidart, J. M.

AU - Bosq, J.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Interest for development of molecular biomarkers tends to increase in clinical management of lung cancer. Indeed implementation in clinics of new molecules targeting epithelial growth factor (EGFR) such as erlotinib or gefitinib, rise several questions regarding the potential value of EGFR and KRAS mutations to predict therapeutic response. In the current review, we discuss the utilization of such biomarkers regarding published clinical data and the possibilities versus limitations associated with analyses performed in molecular laboratory on a daily setting basis.

AB - Interest for development of molecular biomarkers tends to increase in clinical management of lung cancer. Indeed implementation in clinics of new molecules targeting epithelial growth factor (EGFR) such as erlotinib or gefitinib, rise several questions regarding the potential value of EGFR and KRAS mutations to predict therapeutic response. In the current review, we discuss the utilization of such biomarkers regarding published clinical data and the possibilities versus limitations associated with analyses performed in molecular laboratory on a daily setting basis.

UR - http://www.scopus.com/inward/record.url?scp=75549091465&partnerID=8YFLogxK

U2 - 10.1684/bdc.2009.0999

DO - 10.1684/bdc.2009.0999

M3 - Article 'review'

C2 - 20034873

AN - SCOPUS:75549091465

SN - 0007-4551

VL - 96 Suppl

SP - S75-83

JO - Bulletin du Cancer

JF - Bulletin du Cancer

ER -